CHANCE - Candesartan in Hypertrophic Cardiomyopathy
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with
nonobstructive form of HCM will be first save, second will cause regression of myocardial
hypertrophy.